JITC

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
Tamer Basel Shabaneh, Andrew R Stevens, Sylvia M Stull, Kristen R Shimp, Brandon W Seaton, Ekram A Gad, Carla A Jaeger-Ruckstuhl, Sylvain Simon, Amanda L Koehne, Jason P Price, James M Olson, Benjamin G Hoffstrom, David Jellyman, Stanley R Riddell

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008566; DOI: 10.1136/jitc-2023-008566
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Toshihide Ueno, Shinya Kojima, Masashi Wakabayashi, Naoya Sakamoto, Motohiro Kojima, Takeshi Kuwata, Takayuki Yoshino, Hiroyoshi Nishikawa, Hiroyuki Mano, Itaru Endo, Kohei Shitara, Akihito Kawazoe

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008210; DOI: 10.1136/jitc-2023-008210
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, John R. Penrod, Yong Yuan, Adam Lee, Martin Reck

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008189; DOI: 10.1136/jitc-2023-008189
Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
Stephanie N Shishido, Olivia Hart, Sujin Jeong, Aidan Moriarty, Darren Heeke, John Rossi, Adrian Bot, Peter Kuhn

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e007329; DOI: 10.1136/jitc-2023-007329
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types
Jeanne Shen, Yoon-La Choi, Taebum Lee, Hyojin Kim, Young Kwang Chae, Ben W Dulken, Stephanie Bogdan, Maggie Huang, George A Fisher, Sehhoon Park, Se-Hoon Lee, Jun-Eul Hwang, Jin-Haeng Chung, Leeseul Kim, Heon Song, Sergio Pereira, Seunghwan Shin, Yoojoo Lim, Chang Ho Ahn, Seulki Kim, Chiyoon Oum, Sukjun Kim, Gahee Park, Sanghoon Song, Wonkyung Jung, Seokhwi Kim, Yung-Jue Bang, Tony S K Mok, Siraj M. Ali, Chan-Young Ock

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008339; DOI: 10.1136/jitc-2023-008339
Machine learning analysis of pathological images to predict 1-year progression-free survival of immunotherapy in patients with small-cell lung cancer
Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, Akira Sano, Yuka Kitamura, Junya Fukuoka, Yuki Sato, Takashi Kijima, Hirotaka Matsumoto, Toshihide Yokoyama, Satoru Miura, Akito Hata, Motohiro Tamiya, Yoshihiko Taniguchi, Jun Sugisaka, Naoki Furuya, Hisashi Tanaka, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e007987; DOI: 10.1136/jitc-2023-007987
Prognostic and predictive value of angiogenesis-associated serum proteins for immunotherapy in esophageal cancer
Mengting Gao, Xueying Wu, Xi Jiao, Ying Hu, Yanni Wang, Na Zhuo, Fengxiao Dong, Yujiao Wang, Fengyuan Wang, Yanshuo Cao, Chang Liu, Jian Li, Lin Shen, Henghui Zhang, Zhihao Lu

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e006616; DOI: 10.1136/jitc-2022-006616
Cardiovascular toxicities associated with bispecific T-cell engager therapy
Ahmed Sayed, Malak Munir, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Meara, Syed Mahmood, Stephanie Feldman, Eric H Yang, Jiwon Kim, Narendranath Epperla, Daniel Addison

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008518; DOI: 10.1136/jitc-2023-008518
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma
Sujin Zhou, Shiwei Zhang, Kexin Zheng, Zixuan Li, Enyu Hu, Yunping Mu, Jialuo Mai, Allan Zhao, Zhenggang Zhao, Fanghong Li

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e008238; DOI: 10.1136/jitc-2023-008238
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Shengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou

Journal for ImmunoTherapy of Cancer Feb 2024, 12 (2) e007227; DOI: 10.1136/jitc-2023-007227

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages